TREX1 gene changes in lupus with skin rashes
Part of Immune system & allergy, Skin clinical trials.
This trial tests for a specific gene change (in the TREX1 gene) in people with lupus, especially those who have lupus-related skin rashes. It aims to understand how this gene may affect the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 60 years old.
- You must have a diagnosis of lupus (systemic lupus erythematosus) based on the 2019 EULAR/ACR criteria.
- You must have at least one lupus-related skin rash (acute, subacute, or chronic).
- You cannot have other autoimmune diseases like dermatomyositis or systemic sclerosis.
- You cannot have a serious infection, cancer, or be pregnant.
- You cannot have used biologic therapy or strong immunosuppressant pulses in the last month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called CPTX2309, given intravenously, for people with moderate to severe rheumatoid arthritis or systemic lupus erythematosus. It aims to see if the drug is safe and effective.
This study tests a new medicine, TQH3906, in people with systemic lupus erythematosus (SLE) who have moderate to severe disease activity. It aims to see if TQH3906 can safely reduce lupus symptoms like joint pain, skin rash, or vasculitis.
This trial tests a new biologic drug called telitacicept for people with systemic lupus erythematosus (SLE). It aims to see how safe and effective the drug is and may offer a new treatment option for lupus.
This research study aims to better understand systemic lupus erythematosus (SLE), an autoimmune disease where the body's immune system attacks its own tissues. Researchers will evaluate patients with lupus, study genetic factors, and perform optional imaging tests to learn how the disease affects blood vessels and the heart.
This study looks at a “treat-to-target” approach for people with systemic lupus erythematosus (SLE) to help control symptoms to a specific goal. It may help guide medication changes when lupus is not fully calm yet.
This trial tests a new drug called GSK5926371 for people with certain autoimmune diseases that affect the joints, skin, and other tissues. It aims to see if the drug is safe and how well it works.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.